Published in J Clin Oncol on September 27, 2010
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia (2014) 1.47
Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer (2012) 1.29
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol (2015) 1.26
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia (2013) 1.22
Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.19
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One (2012) 1.14
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol (2013) 1.07
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood (2014) 1.04
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol (2013) 0.96
High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant (2011) 0.87
The Philadelphia chromosome in leukemogenesis. Chin J Cancer (2016) 0.86
Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood. Korean J Pediatr (2011) 0.85
Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica (2013) 0.84
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer (2014) 0.84
Synergism of FAK and tyrosine kinase inhibition in Ph(+) B-ALL. JCI Insight (2016) 0.83
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica (2015) 0.83
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol (2016) 0.82
Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatr Hematol Oncol (2014) 0.79
EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2016) 0.78
Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer (2015) 0.78
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol (2012) 0.77
Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia (2015) 0.75
Prognostification of ALL by Cytogenetics. Indian J Hematol Blood Transfus (2014) 0.75
Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia. BMC Med Res Methodol (2013) 0.75
Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric Oncology. JAMA (2015) 0.75
Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol (2014) 0.75
Ikaros: exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia. Exp Hematol (2016) 0.75
Therapies on the horizon for childhood acute lymphoblastic leukemia. Curr Opin Pediatr (2016) 0.75
Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br J Haematol (2016) 0.75
Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia. Chin Med J (Engl) (2017) 0.75
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
Analyzing survival curves at a fixed point in time. Stat Med (2007) 3.11
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia (2009) 2.58
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 2.33
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia (2009) 2.11
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia (2009) 1.99
Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia (2009) 1.90
Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol (2009) 1.86
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia (2009) 1.86
Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia (2009) 1.45
Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer (1997) 1.41
Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia (2009) 1.40
Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia (2009) 1.25
[Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Klin Padiatr (1987) 1.23
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21
Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia (2009) 1.11
Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia (2009) 1.06
'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia (2010) 1.00
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood (1991) 0.95
Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia (2009) 0.94
Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood (1991) 0.83
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34
The tumor lysis syndrome. N Engl J Med (2011) 4.29
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst (2011) 3.51
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol (2008) 3.34
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood (2005) 3.09
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol (2003) 2.88
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet (2010) 2.83
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.75
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60